{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:36:57Z","timestamp":1787161017916,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002002","name":"Cancer Research Foundation","doi-asserted-by":"publisher","award":["17-287"],"award-info":[{"award-number":["17-287"]}],"id":[{"id":"10.13039\/100002002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","award":["1U01FD007909-01A1"],"award-info":[{"award-number":["1U01FD007909-01A1"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["25-20-26-PARE"],"award-info":[{"award-number":["25-20-26-PARE"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011297","name":"United States and Canadian Academy of Pathology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.modpat.2025.100901","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:49:25Z","timestamp":1759211365000},"page":"100901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Human Epidermal Growth Factor Receptor 2 (HER2)-Ultralow Breast Cancer: Incidence, Clinicopathologic Features, and Need for Refined Scoring System"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6030-1679","authenticated-orcid":false,"given":"Doaa","family":"Morrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edi","family":"Brogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fresia","family":"Pareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4677-9398","authenticated-orcid":false,"given":"Dara S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2025.100901_bib1","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"issue":"9","key":"10.1016\/j.modpat.2025.100901_bib2","first-page":"6254","article-title":"Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas","volume":"7","author":"Nassar","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.modpat.2025.100901_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchi\u00f2","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.modpat.2025.100901_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.modpat.2025.100901_bib5","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100901_bib6","doi-asserted-by":"crossref","first-page":"155550","DOI":"10.1016\/j.prp.2024.155550","article-title":"Understanding the spectrum of HER2 status in breast cancer: from HER2-positive to ultra-low HER2","volume":"262","author":"Ahuja","year":"2024","journal-title":"Pathol Res Pract"},{"issue":"8","key":"10.1016\/j.modpat.2025.100901_bib7","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.modpat.2025.100901_bib8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000524227","article-title":"Unusual patterns of HER2 expression in breast cancer: insights and perspectives","volume":"89","author":"Grassini","year":"2022","journal-title":"Pathobiology"},{"issue":"17","key":"10.1016\/j.modpat.2025.100901_bib9","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2025.100901_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10549-023-07020-z","article-title":"The dynamics of HER2-low expression during breast cancer progression","volume":"201","author":"Anderson","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.modpat.2025.100901_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e13156","article-title":"Prevalence of \u201cHER2 ultra-low\u201d among patients with advanced breast cancer with historical IHC0 status","volume":"42","author":"Mehta","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100901_bib12","author":"College of American Pathologists"},{"issue":"22","key":"10.1016\/j.modpat.2025.100901_bib13","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2025.100901_bib14","doi-asserted-by":"crossref","first-page":"104355","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","volume":"198","author":"Mart\u00edn","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.modpat.2025.100901_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/medicina61040719","article-title":"Comparison of clinicopathological characteristics for HER2-null, HER2-ultralow and HER2-low breast cancer: a single-center study","volume":"61","author":"Akay","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.modpat.2025.100901_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13000-024-01557-3","article-title":"Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer","volume":"19","author":"Guan","year":"2024","journal-title":"Diagn Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2025.100901_bib17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4143\/crt.2023.846","article-title":"Recent developments in the therapeutic landscape of advanced or metastatic hormone receptor-positive breast cancer","volume":"55","author":"Lee","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.modpat.2025.100901_bib18","doi-asserted-by":"crossref","first-page":"100032","DOI":"10.1016\/j.modpat.2022.100032","article-title":"Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry","volume":"36","author":"Robbins","year":"2023","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2025.100901_bib19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1309\/AJCP4A7KTAYHZSOE","article-title":"Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance","volume":"140","author":"Lambein","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"17","key":"10.1016\/j.modpat.2025.100901_bib20","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.28710","article-title":"Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer","volume":"120","author":"Kaufman","year":"2014","journal-title":"Cancer"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225001991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225001991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:15:24Z","timestamp":1773252924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395225001991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0893395225001991"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100901","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human Epidermal Growth Factor Receptor 2 (HER2)-Ultralow Breast Cancer: Incidence, Clinicopathologic Features, and Need for Refined Scoring System","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100901","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100901"}}